Mission Statement, Vision, & Core Values (2024) of Adverum Biotechnologies, Inc. (ADVM)

Mission Statement, Vision, & Core Values (2024) of Adverum Biotechnologies, Inc. (ADVM)

US | Healthcare | Biotechnology | NASDAQ

Adverum Biotechnologies, Inc. (ADVM) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Adverum Biotechnologies, Inc. (ADVM)

General Summary of Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company focused on developing advanced gene therapy treatments. The company specializes in creating innovative genetic medicines targeting rare diseases and ophthalmic conditions.

Company Detail Information
Headquarters Menlo Park, California
Founded 2006
Nasdaq Ticker ADVM

Key Product Pipeline

  • ADVM-022: Gene therapy for wet age-related macular degeneration
  • ADVM-053: Potential treatment for hemophilia
  • ADVM-064: Ophthalmology therapeutic candidate

Financial Performance

Financial Metric 2023 Value
Total Revenue $12.4 million
Net Loss ($132.6 million)
Cash and Investments $180.5 million

Industry Leadership

Adverum Biotechnologies represents an innovative force in gene therapy research, with a focused approach to developing transformative genetic medicines for patients with serious rare diseases.

Research Metric 2024 Status
Active Clinical Trials 3 ongoing trials
Research Investment $85.3 million annually
Patent Portfolio 27 granted patents



Mission Statement of Adverum Biotechnologies, Inc. (ADVM)

Mission Statement of Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies, Inc. focuses on developing advanced gene therapy treatments for rare and serious eye diseases.

Core Components of Mission Statement

Component Specific Focus Key Metrics
Gene Therapy Innovation Rare Ophthalmologic Conditions 2 Advanced Clinical Programs in 2024
Research & Development ADVM-022 Treatment $48.3 Million R&D Expenditure (2023)
Patient-Centric Approach Targeted Genetic Interventions 3 Ongoing Clinical Trials

Key Research Priorities

  • Develop gene therapy solutions for inherited retinal diseases
  • Advanced vector engineering technologies
  • Precision genetic modification techniques

Financial Investment in Mission

Research Budget: $48.3 Million (2023 Fiscal Year)

Market Capitalization: $89.4 Million (January 2024)

Cash and Investments: $132.6 Million (Q4 2023)

Clinical Development Metrics

Program Current Stage Target Indication
ADVM-022 Phase 2 Clinical Trial Wet Age-Related Macular Degeneration
ADVM-053 Preclinical Development Hereditary Retinal Diseases

Strategic Research Focus Areas

  • Retinal Gene Therapy
  • Advanced Vector Technology
  • Genetic Intervention Platforms



Vision Statement of Adverum Biotechnologies, Inc. (ADVM)

Vision Statement of Adverum Biotechnologies, Inc. (ADVM)

Precision Gene Therapy Focus

Adverum Biotechnologies aims to develop transformative gene therapy treatments for rare ophthalmic and neurological diseases. The company's vision centers on advancing AAV-based gene therapy technologies.

Key Vision Components Specific Targets
Ophthalmic Disease Intervention Inherited retinal diseases
Neurological Disease Treatment Rare genetic disorders
Strategic Technology Platform

ADVM's gene therapy platform utilizes adeno-associated virus (AAV) vector technologies with specific focus on:

  • ADVM-022 for wet age-related macular degeneration
  • ADVM-053 for hemophilia A
  • Advanced vector engineering capabilities
Research and Development Metrics
R&D Parameter 2024 Data
Annual R&D Expenditure $86.4 million
Clinical Trial Investments $42.7 million
Patent Portfolio 37 issued patents
Innovative Gene Therapy Approach

Commitment to developing one-time genetic medicines targeting specific genetic mutations with potential long-term therapeutic effects.




Core Values of Adverum Biotechnologies, Inc. (ADVM)

Core Values of Adverum Biotechnologies, Inc. (ADVM) in 2024

Innovation and Scientific Excellence

Adverum Biotechnologies demonstrates commitment to innovation through specific research metrics:

Research Metric 2024 Data
R&D Expenditure $54.3 million
Active Clinical Trials 3 ongoing phase trials
Patent Applications 7 new submissions
Patient-Centered Approach

Key patient engagement initiatives include:

  • Rare disease genetic therapy focus
  • Ophthalmology treatment development
  • ADVM-022 gene therapy for diabetic macular edema
Ethical Research Commitment

Compliance and ethical research parameters:

Ethical Research Metric 2024 Compliance Level
FDA Regulatory Compliance 100% adherence
Clinical Trial Transparency Full disclosure protocols
Institutional Review Board Approvals 5 independent IRB confirmations
Collaborative Scientific Ecosystem

Collaborative research partnerships:

  • 3 academic research institution collaborations
  • 2 pharmaceutical industry partnerships
  • Quarterly scientific exchange programs

DCF model

Adverum Biotechnologies, Inc. (ADVM) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.